Spruce Biosciences Reports Positive Long-Term Results for Tralesinidase Alfa in Sanfilippo Syndrome Type B

Reuters

01/28

<a href="https://laohu8.com/S/SPRB">Spruce Biosciences</a> Reports Positive Long-Term Results for Tralesinidase Alfa in Sanfilippo Syndrome Type B

Spruce Biosciences Inc. has announced upcoming presentations of clinical data regarding its investigational enzyme replacement therapy, tralesinidase alfa (TA-ERT), for the treatment of Sanfilippo syndrome type B (MPS IIIB). The data, to be presented at the 22nd Annual WORLDSymposium™ from February 2-6, 2026 in San Diego, will include findings on the long-term administration of TA-ERT, showing its impact on reducing heparan sulfate levels and stabilizing cognitive function and cortical gray matter volume in patients. Additionally, a separate presentation will detail divergent neurocognitive outcomes in two siblings with MPS IIIB, one treated with TA-ERT and the other receiving supportive care. The results have not yet been presented and are scheduled for February 5, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spruce Biosciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260128573673) on January 28, 2026, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2606719752"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2606719752\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2606719752?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-28 21:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2606719752","market":"nz","top_or_hot":-1,"title":"Spruce Biosciences Reports Positive Long-Term Results for Tralesinidase Alfa in Sanfilippo Syndrome Type B","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/SPRB\">Spruce Biosciences</a> Reports Positive Long-Term Results for Tralesinidase Alfa in Sanfilippo Syndrome Type B\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Spruce Biosciences Inc. has announced upcoming presentations of clinical data regarding its investigational enzyme replacement therapy, tralesinidase alfa (TA-ERT), for the treatment of Sanfilippo syndrome type B (MPS IIIB). The data, to be presented at the 22nd Annual WORLDSymposium™ from February 2-6, 2026 in San Diego, will include findings on the long-term administration of TA-ERT, showing its impact on reducing heparan sulfate levels and stabilizing cognitive function and cortical gray matter volume in patients. Additionally, a separate presentation will detail divergent neurocognitive outcomes in two siblings with MPS IIIB, one treated with TA-ERT and the other receiving supportive care. The results have not yet been presented and are scheduled for February 5, 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spruce Biosciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260128573673) on January 28, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Spruce Biosciences Reports Positive Long-Term Results for Tralesinidase Alfa in Sanfilippo Syndrome Type B</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSpruce Biosciences Reports Positive Long-Term Results for Tralesinidase Alfa in Sanfilippo Syndrome Type B\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-28 21:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/SPRB\">Spruce Biosciences</a> Reports Positive Long-Term Results for Tralesinidase Alfa in Sanfilippo Syndrome Type B\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Spruce Biosciences Inc. has announced upcoming presentations of clinical data regarding its investigational enzyme replacement therapy, tralesinidase alfa (TA-ERT), for the treatment of Sanfilippo syndrome type B (MPS IIIB). The data, to be presented at the 22nd Annual WORLDSymposium™ from February 2-6, 2026 in San Diego, will include findings on the long-term administration of TA-ERT, showing its impact on reducing heparan sulfate levels and stabilizing cognitive function and cortical gray matter volume in patients. Additionally, a separate presentation will detail divergent neurocognitive outcomes in two siblings with MPS IIIB, one treated with TA-ERT and the other receiving supportive care. The results have not yet been presented and are scheduled for February 5, 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spruce Biosciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260128573673) on January 28, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260128:nNDL773dGB:1","article_id":"2606719752","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2606719752","pubTimestamp":1769605262,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Spruce Biosciences Inc. has announced upcoming presentations of clinical data regarding its investigational enzyme replacement therapy, tralesinidase alfa , for the treatment of Sanfilippo syndrome type B . The data, to be presented at the 22nd Annual WORLDSymposium from February 2-6, 2026 in San Diego, will include findings on the long-term administration of TA-ERT, showing its impact on reducing heparan sulfate levels and stabilizing cognitive function and cortical gray matter volume in patients. Additionally, a separate presentation will detail divergent neurocognitive outcomes in two siblings with MPS IIIB, one treated with TA-ERT and the other receiving supportive care. The results have not yet been presented and are scheduled for February 5, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and sho","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","SPRB":"Spruce Biosciences, Inc."},"translate_title":"Spruce Biosciences报告曲莱西尼酶α治疗B型Sanfilippo综合征的积极长期结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SPRB":0.9},"content_text":"Spruce Biosciences Reports Positive Long-Term Results for Tralesinidase Alfa in Sanfilippo Syndrome Type B\n    \n\n        Spruce Biosciences Inc. has announced upcoming presentations of clinical data regarding its investigational enzyme replacement therapy, tralesinidase alfa (TA-ERT), for the treatment of Sanfilippo syndrome type B (MPS IIIB). The data, to be presented at the 22nd Annual WORLDSymposium™ from February 2-6, 2026 in San Diego, will include findings on the long-term administration of TA-ERT, showing its impact on reducing heparan sulfate levels and stabilizing cognitive function and cortical gray matter volume in patients. Additionally, a separate presentation will detail divergent neurocognitive outcomes in two siblings with MPS IIIB, one treated with TA-ERT and the other receiving supportive care. The results have not yet been presented and are scheduled for February 5, 2026.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spruce Biosciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260128573673) on January 28, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}